Compartmental transport model of microbicide delivery by an intravaginal ring

Journal of Pharmaceutical Sciences

Volumn 99, Issue 8, 2010, Pages 3514-3521

  Geonnotti, Anthony R ^a,b   Katz, David F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Duke University   (United States)

Author keywords

COMSOL multiphysics; Dapivirine; HIV AIDS; IVR; Transport theory

Indexed keywords

DAPIVIRINE; MICROBICIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TMC120-R147681;

ARTICLE; DRUG TRANSPORT; FLUID FLOW; NUCLEAR MAGNETIC RESONANCE IMAGING; VAGINA; VAGINA DISCHARGE; VAGINA RING; ABSORPTION; ALGORITHM; ANTAGONISTS AND INHIBITORS; BODY FLUID; COMPUTER PROGRAM; COMPUTER SIMULATION; DIFFUSION; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; KINETICS; METABOLISM; MUCOSA;

ABSORPTION; ADMINISTRATION, INTRAVAGINAL; ALGORITHMS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BODY FLUIDS; COMPUTER SIMULATION; DIFFUSION; FEMALE; HIV REVERSE TRANSCRIPTASE; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MUCOUS MEMBRANE; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SOFTWARE; VAGINA;

EID: 77955103248     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22120     Document Type: Article

References (25)

1. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT. 2009. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038.
2. Fichorova RN, Tucker LD, Anderson DJ. 2001. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184:418-428.
3. Lederman MM, Offord RE, Hartley O. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nature Rev Immunol 6:371-382.
4. Haase AT. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nature Rev Immunol 5:783-792.
5. Stone A. 2002. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nature Rev Drug Discov 1:977-985.
6. Klasse PJ, Shattock R, Moore JP. 2008. Antiretroviral drugbased microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 59:455-471. (Pubitemid 351287949)
7. Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, Mitchnik MA, Kiser PF. 2008. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 97: 4228-4239.
8. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. 2006. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 325:82-89.
9. Woolfson AD, Malcolm RK, Toner CF, Morrow RJ, Lowry D, Jamil A, McCullagh SD. 2006. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: A controlled-release strategy for HIV microbicides. Am J Drug Deliv 4:7-20.
10. Malcolm K, Woolfson D, Russell J, Andrews C. 2003. In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J Control Release 91:355-364.
11. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. 2005. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56:954-956.
12. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, Temmerman M, Verstraelen H, Van Bortel L, Weyers S, Mitchnick M. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retrov 25:483-488.
13. Anibal F, Vivian B, Frank A. 2004. Pros and cons of vaginal rings for contraceptive hormone delivery. Am J Drug Deliv 2: 241-250.
14. Roumen FJME, Apter D, Mulders TMT, Dieben TOM. 2001. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Human Reprod 16:469-475. (Pubitemid 32218795)
15. Sarkar NN. 2005. The combined contraceptive vaginal device (NuvaRing):A comprehensive review. Eur J Contracept Reprod Health Care 10:73-78.
16. Weisberg E, Fraser IS, Mishell DR, Jr., Lacarra M, Darney P, Jackanicz TM. 1999. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 59:305-310.
17. Das K, Clark AD, Jr., Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47:2550-2560.
18. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. 2005. In vivo assessment of NuvaRing(R) placement. Contraception 72:196-199.
19. Saltzman WM. 2001. Drug delivery: Engineering principles for drug therapy. 1st edition, New York: Oxford University Press.
20. Barnhart KT, Izquierdo A, Pretorius ES, Shera DM, Shabbout M, Shaunik A. 2006. Baseline dimensions of the human vagina. Human Reprod 21:1618-1622.
21. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59:91-95.
22. st edition. Upper Saddle River: Pearson Prentice Hall.
23. Geonnotti AR, Furlow MJ, Wu T, DeSoto MG, Henderson MH, Kiser PF, Katz DF. 2008. Measuring macrodiffusion coefficients in microbicide hydrogels via postphotoactivation scanning. Biomacromolecules 9:748-751.
24. Rohan LC. February 8, 2008. Personal communication of unpublished data.
25. Roumen FJME. 2008. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manage 4:441-451.